IgG4 - Related diseases Market: Epidemiology, Therapies, Companies, DelveInsight | Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company

IgG4 - Related diseases emerging therapies, such as Obexelimab (XmAb5871), and others, are expected to boost the IgG4 - Related diseases Market in the upcoming years.

DelveInsight has launched a new report on "IgG4 - Related diseases - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the IgG4 - Related diseases, historical and forecasted epidemiology as well as the IgG4 - Related diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the IgG4 - Related diseases market report @ https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the IgG4 - Related diseases Market Report:

The IgG4-Related Disease (IgG4-RD) market was valued at approximately USD 170 million in 2024 and is projected to experience strong growth at a notable CAGR throughout the 2020-2034 forecast period.
IgG4-RD is a systemic fibroinflammatory condition that can involve nearly any organ, most commonly affecting the pancreas, bile ducts, salivary and lacrimal glands, orbits, kidneys, lungs, and retroperitoneum. It is characterized by elevated serum IgG4 levels and infiltration of IgG4-positive plasma cells in affected tissues.
In April 2025, Amgen received FDA approval for UPLIZNA, making it the first approved treatment for adults with IgG4-RD. The drug was granted Breakthrough Therapy Designation due to its potential to address a significant unmet need in treating this chronic, multi-organ disease.
The true prevalence of IgG4-RD remains uncertain, largely due to underrecognition, nonspecific symptoms, and its relatively recent identification. While most cases are diagnosed in men aged 30 to 50, pediatric cases have also been reported. In 2024, there were an estimated 148,970 diagnosed prevalent cases across the 7MM (U.S., EU4, UK, and Japan), with the United States accounting for the largest share.
Japan has been more active in identifying cases, supported by multiple epidemiological studies and national data. Based on 10-year cumulative prevalence data, Japan had approximately 38,690 diagnosed cases in 2024, reflecting a significant increase in diagnoses between 2015 and 2018.
Leading pharmaceutical companies developing therapies for IgG4-RD include Amgen, Zenas BioPharma, Bristol Myers Squibb, Sanofi, and others. Despite therapeutic advancements, 20-30% of diagnosed patients do not receive systemic treatment, opting instead for surgical interventions or being monitored under a watchful waiting approach.
In 2024, the United States recorded approximately 56,800 diagnosed prevalent cases of IgG4-related disease (IgG4-RD), with numbers expected to rise over the 2025-2034 forecast period. Of these, around 39,100 cases were reported in males and 17,700 in females, highlighting a higher prevalence among men.
In April 2025, IgG4-related disease (IgG4-RD)-a systemic fibroinflammatory disorder-gained attention for its involvement across multiple organs, including the pancreas, kidneys, and lungs. The condition is marked by the buildup of IgG4-positive plasma cells in tissues and elevated IgG4 levels in the blood.
In April 2025, Amgen announced that the FDA had approved UPLIZNA as the first treatment for adults with IgG4-RD. The therapy, which addresses a significant unmet medical need, was granted Breakthrough Therapy Designation due to its potential to treat this complex, multi-organ inflammatory disease.
In 2024, the United States held the largest share of the IgG4-related disease (IgG4-RD) market among the 7MM countries, generating approximately USD 90 million.
The combined market size of the EU4 and the UK reached around USD 80 million, with Germany contributing the highest share within the European region.
Meanwhile, Japan's IgG4-RD market was valued at nearly USD 6 million in 2024 and is projected to grow at a notable compound annual growth rate (CAGR) over the forecast period from 2025 to 2034.
Key IgG4 - Related diseases companies such as Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company, and others are evaluating new drugs for IgG4 - Related diseases to improve the treatment landscape.
Promising IgG4 - Related diseases therapies include Obexelimab (XmAb5871), and others.

IgG4 - Related diseases Overview

IgG4-related disease (IgG4-RD) is a chronic, systemic fibroinflammatory condition marked by the dense infiltration of IgG4-positive plasma cells within affected tissues, often accompanied by elevated serum IgG4 levels. This autoimmune disorder can impact a broad range of organs, with hallmark diagnostic features including increased IgG4 levels in the blood and significant infiltration of IgG4-expressing plasma cells in tissues.

While the salivary glands, pancreas, and bile ducts are commonly affected, liver involvement is less frequently reported. IgG4-RD has also been identified in a subset of patients with various other conditions, such as Mikulicz's disease, autoimmune pancreatitis, hypophysitis, Riedel's thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysms, and inflammatory pseudotumors.

IgG4 - Related diseases Market Outlook

The exact cause of IgG4-related disease (IgG4-RD) remains unknown and continues to be a focus of ongoing research. Currently, there are no approved treatments that can cure the condition. Although no therapies had been approved until recently, treatment guidelines were established in the "International Consensus Guidance Statement on the Management and Treatment of IgG4-RD", which outlines diagnostic criteria based on IgG4 levels and provides treatment recommendations.

For patients with active or newly diagnosed IgG4-RD, glucocorticoids are typically the first-line therapy. Treatment often begins with prednisone at 30-40 mg/day, or a weight-based dose of 0.6 mg/kg/day, depending on disease severity and urgency. In some cases, conventional disease-modifying anti-rheumatic drugs (DMARDs) are also used.

Plasmablasts, a type of B-cell precursor, are recognized as key biomarkers in IgG4-RD and other rheumatologic diseases. Monitoring plasmablast levels can help guide B-cell-targeted therapies and track disease activity.

With multiple new therapies in development, the treatment landscape for IgG4-RD is expected to undergo significant transformation over the coming years. However, the success of these pipeline therapies will largely depend on pricing, reimbursement, and market accessibility.

Leading pharmaceutical companies such as Zenas BioPharma, Amgen, and Sanofi are actively advancing their investigational candidates through various stages of clinical trials, aiming to bring innovative therapies to market for this challenging autoimmune condition.

Discover how the IgG4 - Related diseases market is rising in the coming years @ https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

IgG4-Related Disease Marketed Drugs
UPLIZNA (inebilizumab): Amgen

IgG4 - Related diseases Emerging Drugs
Obexelimab (XmAb5871): Zenas BioPharma and Bristol Myers Squibb

Scope of the IgG4 - Related diseases Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key IgG4 - Related diseases Companies: Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company, and others
Key IgG4 - Related diseases Therapies: Obexelimab (XmAb5871), and others
IgG4 - Related diseases Therapeutic Assessment: IgG4 - Related diseases current marketed and IgG4 - Related diseases emerging therapies
IgG4 - Related diseases Market Dynamics: IgG4 - Related diseases market drivers and IgG4 - Related diseases market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
IgG4 - Related diseases Unmet Needs, KOL's views, Analyst's views, IgG4 - Related diseases Market Access and Reimbursement

To know what's more in our IgG4 - Related diseases report, visit https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the IgG4 - Related diseases Market Report:
IgG4 - Related diseases market report covers a descriptive overview and comprehensive insight of the IgG4 - Related diseases Epidemiology and IgG4 - Related diseases market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The IgG4 - Related diseases market report provides insights into the current and emerging therapies.
The IgG4 - Related diseases market report provides a global historical and forecasted market covering drug outreach in 7MM.
The IgG4 - Related diseases market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the IgG4 - Related diseases market.

Got queries? Click here to know more about the IgG4 - Related diseases market Landscape https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. IgG4 - Related diseases Patient Share (%) Overview at a Glance
5. IgG4 - Related diseases Market Overview at a Glance
6. IgG4 - Related diseases Disease Background and Overview
7. IgG4 - Related diseases Epidemiology and Patient Population
8. Country-Specific Patient Population of IgG4 - Related diseases
9. IgG4 - Related diseases Current Treatment and Medical Practices
10. Unmet Needs
11. IgG4 - Related diseases Emerging Therapies
12. IgG4 - Related diseases Market Outlook
13. Country-Wise IgG4 - Related diseases Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. IgG4 - Related diseases Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about IgG4 - Related diseases Market Outlook 2034 https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

IgG4 - Related diseases Pipeline Insights, DelveInsight

"IgG4 - Related diseases Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the IgG4 - Related diseases market. A detailed picture of the IgG4 - Related diseases pipeline landscape is provided, which includes the disease overview and IgG4 - Related diseases treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.